A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of HIP0612 in Patients with Gastric Ulcer
Latest Information Update: 25 Feb 2025
At a glance
- Drugs HIP 0612 (Primary)
- Indications Gastric ulcer
- Focus Registrational; Therapeutic Use
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 19 Feb 2025 Status changed from recruiting to completed.
- 08 Oct 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 08 Oct 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.